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Letters to the Editor 
Dear Editor 
NK cells in non-neoplastic lung tissue. Initial results 
The importance of NK cells in the host response 
against tumours is known, but these cells have not 
been accurately studied in non-neoplastic lung tissue 
(1,2). The aim of this study is to evaluate the presence 
of NK cells in non-neoplastic lung tissue. 
Twelve lung biopsies of patients with non- 
neoplastic disease were analysed. No patients had 
received previous radiation and none of them had 
acute inflammatory disease. Historical analysis was 
done in paraffin-embedded sections. Immunohisto- 
chemical stains were performed for NK cells using 
the monoclonal antibody IOT-10 (CD 56). The 
number of NK cells was counted with a MICRON 
image analyzer. 
The total area measured for each biopsy was 
447590pm’. In this area, we deducted the alveolar 
air space, by digital technology. The mean area of 
the interstitial tissue studied was 293840pm’ 
(minimum=234413 and maximum=362108). 
In the biopsies analysed, the number of NK cells 
was between 2 and 13 (mean value = 1.97/100000 pm’; 
minimum=0.68 and maximum=3.59). 
We conclude there are few NK cells in non- 
neoplastic lung tissue free from inflammatory 
disease. 
L.CALLOL,S. COCA, M.J.CHILLON, 
F,VILLEGAS, F. MORENO-MURO AND 
F. J. GOMEZ-TERREROS 
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Dear Editor 
Turbuhaler or nebulizer therapy in severe COPD 
I read with interest the paper by Hansen et al. (1). 
They present evidence that high dose bronchodilator 
therapy given by dry powder inhaler can be as 
effective as nebulizer therapy. This fits well with their 
own previous comparisons of nebulized and dry 
powder therapy and the paper is in agreement with 
studies that have shown that high dose broncho- 
dilator therapy is equally effective whether given by 
nebulizer or by metered dose inhaler. 
The authors are correct in stating that dry powder 
therapy is more convenient for the patient than 
nebulizer therapy but, unfortunately, it is my experi- 
ence that most U.K. COPD patients with home 
nebulizers tend to use a combination of p-agonist and 
anti-cholinergic therapy. 
Unfortunately, the latter cannot be given by dry 
powder at present (at least in the U.K.). The benefits of 
convenience would therefore be lost for many patients. 
More importantly, the discussion contains a mis- 
leading statement that ‘the costs of dry powder treat- 
ment are considerably less than the cost of domiciliary 
nebulizer therapy.’ This statement is very inaccurate 
for U.K. prescribers. The present cost of terbutaline 
treatment is as follows: Bricanyl respirator solution 
5 mg qid costs f96.00 per annum. Bricanyl respules 
5Omg qid would cost E267.00 per annum. Bricanyl 
turbohaler 2.5 mg qid would cost E652.00 per annum. 
Although the nebulizer user would have an initial 
cost of approximately ~&100.00 to purchase a com- 
pressor and some small running costs for disposable 
items, the dry powder treatment is either twice as 
expensive or six times as expensive depending on 
which nebulizer product is used. 
A switch to dry powder treatment would not 
therefore be an economically attractive option for 
U.K. prescribers and I would be interested if the 
authors would give comparative costs for treatment 
in Denmark and in other countries where the dry 
powder preparation is available. 
R. O'DRISCOLL 
General and Respiratory Medicine 
Hope Hospital 
Salford M6 SHD, U.K. 
19 May 1994 
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P.S. (November 1994) Ipratropium dry powder therapy has 
now been introduced to the U.K. market. 
Reply to Dr O’Driscoll 
In Denmark and a number of other European 
countries, anti-cholinergic dry powder therapy is 
available. Ipratropium is inhaled by the Inhalator 
Ingelheim, either alone (Atrovent capsules, 40 mg) or 
as a fixed combination (Berodual capsules with 40 mg 
ipratropium + 100 mg fenoterol). For patients with 
severe COPD, I usually recommend ipratropium dry 
powder 4&80 mg four times per day in combination 
with a short acting &stimulator (as dry powder) 
taken as needed. We seldom prescribe a nebulizer 
anymore, and during the last 5 yr the number of 
adult nebulizer users in the local area has decreased 
from about 330 to less than 220. 
Astra Draco AB, Sweden has kindly supplied data 
for countries where terbutaline (Bricanyl) is available 
both as Turbuhaler and as respules, and I have 
calculated the following ratios between the prices of 
2.5 mg terbutaline from Turbuhaler (=five doses) 
and 5 mg terbutaline nebulizer solution (= 1 respule): 
Denmark: 0.37, Sweden: 0.75, Norway: 0.80, Iceland: 
0.81, Australia: 1.01, Switzerland: 1.14, U.K.: 2.846. 
The great difference between Denmark and U.K. 
prices is mainly due to a much lower price of 
nebulizer solution in the U.K. 
N. C. G. HANSEN 
Department of Respiratory Diseases (C) 
Odense University Hospital 
DK-5000 Odense C, Denmark 
Dear Editor 
Flumazenil to reverse midazolam sedation 
Williams et al. (1) report the use of high dose 
intravenous midazolam for sedation during fibreoptic 
bronchoscopy. Although the mean dose used of 
0.24 f 0.1 mg kg - ’ is within the recommended range 
for the induction of anaesthesia, some patients 
received over twice this dose, with the upper range 
being 0.67 mg kg - ’ . 9.8% of the total 123 patients 
were given intravenous flumazenil to reverse the 
effects of midazolam because there were insufficient 
nursing staff available to look after recovery patients. 
This is of concern, firstly because the side-effects of 
flumazenil are nausea, vomiting, agitation, flushing, 
anxiety and fear: the very sensations this technique is 
trying to avoid. Secondly, flumazenil is very short- 
acting, and when high doses of midazolam are used, 
with an average half-life of 2 h, repeated doses of 
flumazenil may have to be given. Therefore it would 
seem that nursing or medical staff would need to 
observe closely these patients after bronchoscopy, 
rather than using this as a method of reducing the 
need for observation. 
F. M. HARDINGE 
Osler Chest Unit 
Churchill Hospital 
Headington 
Oxford, U.K. 
28 June 1994 
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Reply to Dr Hardinge 
Dr Hardinge makes two valid points about the use 
of intravenous flumazenil to reverse the effects of 
midazolam sedation. 
We did not specifically ask patients about possible 
side effects after using flumazenil, but judged from 
our questionnaire those patients who did not fmd the 
procedure any more unpleasant than patients not 
given flumazenil 
Certainly, flumazenil has a shorter half life than 
midazolam, but in practice this did not seem to be a 
problem and no patient needed repeated doses of 
flumazenil. 
However, we are now fortunate in having the 
use of a fully staffed Day Case Unit so only use 
flumazenil when worried about a patient’s condition, 
e.g. when there is a lot of bleeding. 
I was very grateful to Dr Hardinge for raising these 
points. 
T. J. WILLIAMS 
Kettering General Hospital NHS Trust 
Rothwell Road 
Kettering 
Northamptonshire NN16 8UZ U.K. 
